Home›Neurology› New consensus algorithm guides JAK inhibitor choice for alopecia areata
New consensus algorithm guides JAK inhibitor choice for alopecia areataNew treatment plan helps patients with hair loss condition
Frontiers in MedicinePublished July 19, 2026Study authors: Charles W. Lynde, Lyn Guenther, Anneke Andriessen, Sameh Hanna, Elena Netchiporouk, Vimal Prajapati,…DOI ↗Editorial oversight: Dr. Ji-eun Park, MD · Brain, Mind & Pain
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider this algorithm for JAK inhibitor selection in alopecia areata, but note long-term safety data are lacking.
This guideline presents a practical treatment algorithm for alopecia areata developed by a panel of expert dermatologists using a modified Delphi method. The algorithm incorporates SALT scores, quality-of-life impact, and disease progression rate to guide therapy selection. It includes ritlecitinib, approved for adolescents and adults aged 12 years and older, and baricitinib, approved for adults aged 18 years and older.
The algorithm aims to help clinicians deliver personalized, safe care by using broader definitions of disease severity. The authors note that questions on the long-term safety of ritlecitinib and baricitinib remain to be addressed. No specific efficacy data, adverse events, or comparative outcomes are reported in this consensus-based publication.
Clinicians may use this algorithm as a framework for treatment decisions, but should interpret it with caution given the lack of long-term safety data and the absence of direct comparative evidence between the two JAK inhibitors. The guideline does not replace individualized clinical judgment.
How this fits prior evidence
This consensus algorithm extends prior coverage on JAK inhibitors in alopecia areata by providing a structured treatment framework. It complements the real-world meta-analysis of baricitinib for atopic dermatitis (May 2026) and the promising results of upadacitinib for concurrent atopic dermatitis, vitiligo, and alopecia areata (Jun 2026). However, unlike those reports, this guideline does not provide efficacy or safety data, and long-term safety concerns remain, consistent with the network meta-analysis on SLE (May 2026) that noted the need for long-term data.
Living with alopecia areata can be a heavy emotional burden. To help manage this, experts have created a new treatment plan to give patients more personalized care. This approach looks beyond just hair loss by considering how much the condition affects a person's daily life and how fast it is moving.
The guide focuses on two specific medications: ritlecitinib and baricitinib. Ritlecitinib is approved for both adults and adolescents aged 12 and older. Baricitinib is currently approved for use in adults aged 18 and older. These options are part of a new system designed to help doctors make clearer decisions based on the severity of each person's case.
While these tools offer a more tailored way to treat hair loss, there are still some unknowns. Because these medications are newer in this context, experts note that we do not yet have enough information regarding their long-term safety. Patients should talk with their doctors to see how these options fit into their specific care plan.
What this means for you:
A new expert guide helps doctors provide more personalized treatment for people with alopecia areata.
Common questions
What medications are included in this new treatment plan?
The plan includes two medications: ritlecitinib and baricitinib. Ritlecitinib is approved for adults and adolescents aged 12 and older. Baricitinib is currently approved for use in adults who are at least 18 years old.
How does this new approach differ from standard care?
Instead of just looking at hair loss, this plan uses a special scoring system to look at how much the disease affects a person's quality of life and how fast it is progressing. This helps doctors provide more personalized care.
Is it safe to use these medications long-term?
While these options are part of a new treatment plan, the long-term safety of ritlecitinib and baricitinib is not yet established. You should talk with your doctor about the risks and benefits for your specific situation.
Alopecia areata (AA) is an autoimmune, inflammatory condition characterized by non-scarring hair loss on the scalp, face, or body. It can significantly affect a person’s quality of life (QoL) and mental health.
Using a modified Delphi method, a panel of expert dermatologists developed a practical treatment algorithm to help clinicians deliver personalized, safe care to diverse patients with AA.
The approach to the algorithm introduces a broader definition of disease severity, incorporating not only Severity of Alopecia Tool (SALT) scores but also quality-of-life impact and the rate of disease progression.
Recent therapeutic advances have expanded access to effective, safe treatments for a broader population of AA patients. Ritlecitinib, a Janus kinase 3/TEC inhibitor, is currently the only oral Janus kinase inhibitor approved for adolescents and adults aged 12 years and older, whereas baricitinib, a Janus kinase1/2 inhibitor, is approved for adults aged 18 years and older. However, questions on the long-term safety of these therapies, access, and personalization still need to be addressed.
Future efforts should validate and refine the algorithm across real-world cohorts and ensure equitable access to personalized treatment for patients with AA.
